了解患有癌症儿童的诊断延迟:来自约旦单一机构的证据
Anwar Al-Nassan1, Tariq Almanaseer1, Saja Malkawi2
1Department of Pediatrics, King Hussein Cancer Center.
Journal of pediatric hematology/oncology
|August 14, 2024
概括
中枢神经系统瘤和年龄较大显著延迟了儿童癌症的诊断. 像白和黄这样的可见症状加速了医疗照顾,改善了儿童的及时癌症诊断.
科学领域:
- 儿科瘤学 儿科瘤学
- 流行病学 流行病学
- 临床研究 临床研究
背景情况:
- 儿童癌症的诊断延迟是影响治疗结果的重大挑战.
- 了解导致诊断延迟的因素对于改善瘤学患者护理至关重要.
研究的目的:
- 评估在约旦主要机构治疗的儿科癌症患者诊断延迟相关的因素.
- 识别延迟诊断的预测因素,以告知有针对性的干预措施.
主要方法:
- 在2018年8月至2021年12月期间诊断的202名儿科癌症患者的跨截面研究与回顾性图表审查.
- 通过对患者/家庭特征,病史和诊断延迟进行结构化采访收集的数据.
- 用于识别延迟预测因素的单变量和多变量回归模型.
主要成果:
- 从症状出现到开始治疗的平均总延迟时间为47天.
- 中枢神经系统 (CNS) 瘤 (P=0.002) 和老年患者年龄 (P=0.025) 是增加延迟的显著预测因素.
- 可见的症状如白 (P=0.011),伤 (P<0.001) 和黄 (P=0.045) 与较短的延迟有关.
结论:
- 中枢神经系统瘤的诊断,患者年龄和特定症状是儿童瘤学诊断延迟的关键预测因素.
- 调查结果强调,需要针对医疗保健专业人员和家庭制定有针对性的教育计划,以加快识别和转诊.
- 减少诊断延迟对于改善癌症儿童治疗结果至关重要.
相关概念视频
Cancer
51.8K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.8K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
982
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
982
Pharmacokinetics in Pediatric Patients: Drug Distribution
562
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
562
Pharmacokinetics in Pediatric Patients: Drug Metabolism
417
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
417
Pharmacokinetics in Pediatric Patients: Drug Excretion
414
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
414
Cancer Survival Analysis
870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870


